Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any juvenile glaucoma in which the cause of the disease is a mutation in the MYOC gene.
Features include: Abnormal iris vasculature, Glaucoma, and Myopia.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 1 | Abnormal iris vasculature |
Eyes | 1 | Glaucoma |
MYOC encodes myocilin (504 aa). Secreted glycoprotein regulating the activation of different signaling pathways in adjacent cells to control different processes including cell adhesion, cell-matrix adhesion, cytoskeleton organization and cell migration. Highest expression in Esophagus Gastroesophageal Junction (301.4 TPM) and Nerve Tibial (260.2 TPM).
Glaucoma 1, open angle, A is associated with mutations in the MYOC gene on chromosome 1.
The MYOC protein participates in Expression of MYOCD in cardiogenesis, FOXO4, MEF2C, and NKX2-5 bind the MYOCD gene, and Myoclonic epilepsy of Lafora pathways.
MYOC is classified as a druggable target (Druggable Genome and Kinase categories) with score 0.0.
Genetic testing for MYOC is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for glaucoma 1, open angle, A has been reported in the published literature.
No clinical trials have been registered for glaucoma 1, open angle, A.
122 publications have been identified in PubMed for glaucoma 1, open angle, A. Research spans Epidemiology / Natural History (34%), Basic Science / Preclinical (25%), and Clinical Trial Publication (17%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 42 | 34% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:59 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Laboratory research
30 |
25% |
Clinical study results | 21 | 17% |
Patient case studies | 11 | 9% |
Research summaries | 7 | 6% |
New treatment approaches | 6 | 5% |
Testing and diagnosis research | 3 | 2% |
Other research | 2 | 2% |
Karimi A (2026). [PMID: 42007053](https://pubmed.ncbi.nlm.nih.gov/42007053/). *ACS Meas Sci Au*. [Basic Science / Preclinical]
Huang YC (2026). [PMID: 41016521](https://pubmed.ncbi.nlm.nih.gov/41016521/). *American journal of ophthalmology*. [Epidemiology / Natural History]
Sampath Kumar D (2026). [PMID: 41782702](https://pubmed.ncbi.nlm.nih.gov/41782702/). *Clin Nephrol Case Stud*. [Case Report / Case Series]
Nakagawa S (2026). [PMID: 41533258](https://pubmed.ncbi.nlm.nih.gov/41533258/). *Jpn J Ophthalmol*. [Clinical Trial Publication]
Mosos JD (2026). [PMID: 41400991](https://pubmed.ncbi.nlm.nih.gov/41400991/). *J Glaucoma*. [Epidemiology / Natural History]
Klabe K (2026). [PMID: 41902904](https://pubmed.ncbi.nlm.nih.gov/41902904/). *Graefes Arch Clin Exp Ophthalmol*. [Case Report / Case Series]
Nadeem S (2026). [PMID: 41770405](https://pubmed.ncbi.nlm.nih.gov/41770405/). *International ophthalmology*. [Case Report / Case Series]
Hong AT (2026). [PMID: 41360342](https://pubmed.ncbi.nlm.nih.gov/41360342/). *American journal of ophthalmology*. [Epidemiology / Natural History]
Maxwell GE (2026). [PMID: 42096227](https://pubmed.ncbi.nlm.nih.gov/42096227/). *JAMA Ophthalmol*. [Gene Therapy / Novel Therapeutics]
Elhusseiny AM (2026). [PMID: 41974319](https://pubmed.ncbi.nlm.nih.gov/41974319/). *Am J Ophthalmol*. [Epidemiology / Natural History]